A study reveals that the delayed mental health benefits of SSRI antidepressants may be due to physical brain changes leading to enhanced brain plasticity during the first weeks of SSRI consumption. Using PET scans on volunteers, the researchers found a noticeable increase in synapse density in the brains of those taking SSRIs compared to those on a placebo.
Researchers have uncovered that the weeks-long delay in SSRI antidepressant benefits may stem from increased brain plasticity and synapse density over initial weeks of intake, offering new insights into the drug’s workings and onset timing.
SSRI antidepressants normally take a few weeks before any showing mental health benefits, but how come it takes so long? Now a study from a group of clinicians and scientists provides the first human evidence that this is due to physical changes in the brain leading to greater brain plasticity developing over the first few weeks of SSRI intake. This may also begin to explain one of the mechanisms of how antidepressants work.
This work was presented at the ECNP conference in Barcelona on October 9th. This work is also due to be published (has been accepted) in a peer-reviewed journal.
Selective Serotonin Reuptake Inhibitors (SSRIs) are a class of drugs commonly prescribed for depression and other mood disorders. Here are some common SSRIs:
- Fluoxetine (often known by its brand name Prozac)
- Citalopram (brand name Celexa)
- Escitalopram (brand name Lexapro)
- Paroxetine (brand names include Paxil, Pexeva)
- Sertraline (brand name Zoloft)
- Fluvoxamine (brand name Luvox)
Research Details and Methodology
Doctors have been puzzled as to why Selective Serotonin Reuptake Inhibitors (SSRIs) take time before having an effect. Researchers in Copenhagen, Innsbruck, and University of Cambridge have undertaken a randomized, double-blind placebo-controlled study in a group of healthy volunteers which shows a gradual difference in how many nerve cell connections (synapses) the brain cells have between those taking the antidepressants and a control group, depending on how long the treatment lasts.
17 volunteers were given a 20mg daily dose of the SSRI escitalopram, with 15 volunteers given a placebo. Between 3 and 5 weeks after starting the trial, their brains were scanned with a PET (Positron Emission Tomography) scanner, which showed the amount of synaptic vesicle glycoprotein 2A in the brain: this is an indicator of the presence of synapses, so the more of the protein is found in an area, the more synapses are present in that area (i.e., greater synaptic density). These scans showed significant between-group differences in how the synapse density evolved over time.
Location of the neocortex and hippocampus. Credit: Marc Dingman, Neuroscientifically Challenged
Key Findings and Expert Comments
Researcher Professor Gitte Knudsen (of Copenhagen University Hospital) said: “We found that with those taking the SSRI, over time there was a gradual increase in synapses in the neocortex and the hippocampus of the brain, compared to those taking placebo. We did not see any effect in those taking placebo.”
The neocortex takes up around half of the brain’s volume; it is a complex brain structure that deals with higher functions, such as sensory perception, emotion, and cognition. The hippocampus, which is found deep in the brain, functions with memory and learning.
Professor Knudsen continued, “This points towards two main conclusions. Firstly, it indicates that SSRIs increase synaptic density in the brain areas critically involved in depression. This would go some way to indicating that the synaptic density in the brain may be involved in how these antidepressants function, which would give us a target for developing novel drugs against depression. The second point is that our data suggest that synapses build up over a period of weeks, which would explain why the effects of these drugs take time to kick in.”
Commenting, Professor David Nutt (Imperial College, London) said “The delay in therapeutic action of antidepressants has been a puzzle to psychiatrists ever since they were first discerned over 50 years ago. So these new data in humans that uses cutting edge brain imaging to demonstrate an increase in brain connections developing over the period that the depression lifts are very exciting. Also, they provide more evidence enhancing serotonin function in the brain can have enduring health benefits.”
This is an independent comment, Professor Nutt was not involved in this work.
The conference abstract, “Escitalopram increases synaptic density in the human brain over weeks,” (Johansen et al) can be seen at https://www.ecnp.eu/congress2023/ECNPcongress/programme/programme#!abstractdetails/0000552740
This work has also been accepted in a peer-reviewed journal. Unfortunately, it is still in the final stages of the publication process, so we are not yet allowed to give publication details.
This makes a lot more sense than the effect simply being due to increasing amounts of serotonin in the brain, which was long assumed to be the case, but was recently challenged.
It has always been speculated that the delay in ssri effect is due to the mostly nonlinear kinetics which lead to the drugs increased volume of distribution.